Screener
Vertex Pharmaceuticals VRTX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Vertex Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's debt-to-equity?
- Vertex Pharmaceuticals (VRTX) reported debt-to-equity of 0.1× in Q2 2026.
- How has Vertex Pharmaceuticals's debt-to-equity changed year-over-year?
- Vertex Pharmaceuticals's debt-to-equity increased by 9.9% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Vertex Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's debt-to-equity has grown at a 0.1% compound annual growth rate (CAGR), from 0.1× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Vertex Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude